JP2020518256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518256A5 JP2020518256A5 JP2019560197A JP2019560197A JP2020518256A5 JP 2020518256 A5 JP2020518256 A5 JP 2020518256A5 JP 2019560197 A JP2019560197 A JP 2019560197A JP 2019560197 A JP2019560197 A JP 2019560197A JP 2020518256 A5 JP2020518256 A5 JP 2020518256A5
- Authority
- JP
- Japan
- Prior art keywords
- crrna
- cell
- genetically modified
- stem
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 37
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 241001112693 Lachnospiraceae Species 0.000 claims description 5
- 238000010362 genome editing Methods 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 210000004986 primary T-cell Anatomy 0.000 claims description 5
- 238000004520 electroporation Methods 0.000 claims description 4
- 241000194036 Lactococcus Species 0.000 claims description 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 241000604451 Acidaminococcus Species 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 238000009172 cell transfer therapy Methods 0.000 claims description 2
- 238000011519 second-line treatment Methods 0.000 claims description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023092842A JP7622138B2 (ja) | 2017-05-04 | 2023-06-06 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
| JP2025005127A JP2025061285A (ja) | 2017-05-04 | 2025-01-15 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501371P | 2017-05-04 | 2017-05-04 | |
| US62/501,371 | 2017-05-04 | ||
| PCT/US2018/030644 WO2018204493A1 (en) | 2017-05-04 | 2018-05-02 | Compositions and methods for gene editing in t cells using crispr/cpf1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023092842A Division JP7622138B2 (ja) | 2017-05-04 | 2023-06-06 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518256A JP2020518256A (ja) | 2020-06-25 |
| JP2020518256A5 true JP2020518256A5 (https=) | 2021-06-10 |
| JP7292213B2 JP7292213B2 (ja) | 2023-06-16 |
Family
ID=64016339
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560197A Active JP7292213B2 (ja) | 2017-05-04 | 2018-05-02 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
| JP2023092842A Active JP7622138B2 (ja) | 2017-05-04 | 2023-06-06 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
| JP2025005127A Pending JP2025061285A (ja) | 2017-05-04 | 2025-01-15 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023092842A Active JP7622138B2 (ja) | 2017-05-04 | 2023-06-06 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
| JP2025005127A Pending JP2025061285A (ja) | 2017-05-04 | 2025-01-15 | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12029760B2 (https=) |
| EP (1) | EP3619302A4 (https=) |
| JP (3) | JP7292213B2 (https=) |
| CN (1) | CN110785489A (https=) |
| CA (1) | CA3062165A1 (https=) |
| WO (1) | WO2018204493A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| CN110214183A (zh) | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
| WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| KR102622411B1 (ko) | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| BR112020006601A2 (pt) * | 2017-10-02 | 2020-12-08 | Genedit Inc. | Rna guia de cpf1 modificado |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| WO2020122104A1 (ja) | 2018-12-11 | 2020-06-18 | 国立大学法人京都大学 | ゲノムｄｎａに欠失を誘導する方法 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
| US20230248768A1 (en) * | 2020-07-15 | 2023-08-10 | Nanjing Bioheng Biotech Co., Ltd | Engineered immune cell for allotransplantation |
| WO2024038168A1 (en) * | 2022-08-19 | 2024-02-22 | UCB Biopharma SRL | Novel rna-guided nucleases and nucleic acid targeting systems comprising such |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170335331A1 (en) * | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
| EP3215623A4 (en) * | 2014-11-06 | 2018-09-26 | President and Fellows of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| GB2592821B (en) * | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| US20190048340A1 (en) | 2015-09-24 | 2019-02-14 | Crispr Therapeutics Ag | Novel family of rna-programmable endonucleases and their uses in genome editing and other applications |
-
2018
- 2018-05-02 CN CN201880042161.3A patent/CN110785489A/zh active Pending
- 2018-05-02 JP JP2019560197A patent/JP7292213B2/ja active Active
- 2018-05-02 US US16/609,628 patent/US12029760B2/en active Active
- 2018-05-02 CA CA3062165A patent/CA3062165A1/en active Pending
- 2018-05-02 WO PCT/US2018/030644 patent/WO2018204493A1/en not_active Ceased
- 2018-05-02 EP EP18795128.0A patent/EP3619302A4/en active Pending
-
2023
- 2023-06-06 JP JP2023092842A patent/JP7622138B2/ja active Active
-
2024
- 2024-06-12 US US18/740,688 patent/US20240316107A1/en active Pending
-
2025
- 2025-01-15 JP JP2025005127A patent/JP2025061285A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518256A5 (https=) | ||
| Porto et al. | Base editing: advances and therapeutic opportunities | |
| AU2016276702B2 (en) | CRISPR/CAS-related methods and compositions for improving transplantation | |
| CN110139675B (zh) | 用具有工程化稳定的内源性foxp3基因表达的cd4t细胞治疗自身免疫疾病的方法 | |
| JP2019500043A5 (https=) | ||
| JP2018522072A5 (https=) | ||
| JP2016500262A5 (https=) | ||
| JP2020528738A (ja) | ｉｎ ｖｉｔｒｏでＴ細胞中のターゲット遺伝子をノックアウトするための方法及び前記方法で使用されるｃｒＲＮＡ | |
| Zych et al. | Application of genome editing techniques in immunology | |
| CN113646006A (zh) | 用于营养不良型大疱性表皮松解症的治疗剂 | |
| Yang et al. | Optimized two‐step electroporation process to achieve efficient nonviral‐mediated gene insertion into primary T cells | |
| AU2021300358A1 (en) | Methods and compositions for editing the B2M locus in B cells | |
| Kleinstiver et al. | 731. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects | |
| CN113226336B (zh) | 一种在细胞中递送基因的方法 | |
| JP2005521632A5 (https=) | ||
| Ma et al. | Get ready for the CRISPR/Cas system: A beginner's guide to the engineering and design of guide RNAs | |
| Lal et al. | Curative Therapy of Sickle Cell Disease Using Gene Editing Technologies | |
| CN117683722A (zh) | 一种治疗性细胞或其前体细胞的制备方法 | |
| Goryaev et al. | Genome-editing and biomedical cell products: current state, safety and efficacy | |
| US20230272431A1 (en) | Methods and compositions for editing the b2m locus in b cells | |
| O’Brien et al. | CRISPR-mediated gene editing for the surgeon scientist | |
| Liao et al. | Gene editing in hematopoietic stem cells | |
| CN118355348A (zh) | 乙型肝炎病毒(hbv)敲除 | |
| JP2022543139A5 (https=) | ||
| CN114369621B (zh) | 一种基因生物制剂及其制备方法和应用 |